ABVC BioPharma (ABVC) Proxy filing summary

Executive summary

• Special meeting scheduled for October 28, 2026, to be held virtually for shareholder participation and efficiency.

• Three key proposals: approval of a new equity incentive plan, ratification of recent equity awards, and authorization for potential share issuance for property acquisition in Taiwan.

• Board unanimously recommends voting in favor of all proposals.

• Record date for voting is September 14, 2026, with 26,694,476 shares outstanding.

Voting matters and shareholder proposals

• Proposal 1: Approve the 2026 Equity Incentive Plan, replacing the 2016 plan and introducing a new share reserve formula and evergreen provision.

• Proposal 2: Ratify equity awards (600,000 shares) granted to two advisors between February 16 and September 11, 2026.

• Proposal 3: Authorize issuance of up to 1,600,653 shares at no less than $1.00 per share for acquisition of land in Taoyuan and Hualien, Taiwan, in compliance with Nasdaq rules.

• All proposals require a majority of votes cast for approval.

Board of directors and corporate governance

• Board members, including Ms. Shuling Jiang, are involved in the proposed property transaction, triggering related-party review.

• Audit Committee will review and approve the related-party transaction as per company and Nasdaq governance requirements.